Retinal changes in an experimental model of early type 2 diabetes in rats characterized by non-fasting hyperglycemia

Experimental Neurology

Volumn 236, Issue 1, 2012, Pages 151-160

  Salido, Ezequiel M ^a   de Zavalía, Nuria ^a   Schreier, Laura ^b   De Laurentiis, Andrea ^c   Rettori, Valeria ^c   Chianelli, Mónica ^a   Keller Sarmiento, María Inés ^a   Arias, Pablo ^d   Rosenstein, Ruth E ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Diabetic retinopathy; Electroretinogram; Experimental model; Type 2 diabetes mellitus

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; INSULIN; NITRIC OXIDE SYNTHASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ELECTRORETINOGRAM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVOKED VISUAL RESPONSE; EXPERIMENTAL MODEL; EYE EXAMINATION; FUNCTIONAL MORPHOLOGY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID PEROXIDATION; MALE; MICROSCOPY; MUELLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HUMANS; HYPERGLYCEMIA; MALE; RATS; RATS, WISTAR;

EID: 84861677260     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.04.010     Document Type: Article

References (44)

1. Aiello L.P., Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int. 2000, 77:S113-S119.
2. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2008, 31:S55-S60.
3. Arevalo J.F., Fromow-Guerra J., Quiroz-Mercado H., Sanchez J.G., Maia M., Berrocal M.H., Solis-Vivanco A., Farah M.E. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007, 114:743-750. Pan-American Collaborative Retina Study Group.
4. Ayala J.E., Bracy D.P., McGuinness O.P., Wasserman D.H. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 2006, 55:390-397.
5. Belforte N., Moreno M.C., Cymeryng C., Bordone M., Keller Sarmiento M.I., Rosenstein R.E. Effect of ocular hypertension on retinal nitridergic pathway activity. Invest. Ophthalmol. Vis. Sci. 2007, 48:2127-2133.
6. Bray G.A. Medical consequences of obesity. J. Clin. Endocrinol. Metab. 2004, 89:2583-2589.
7. Bresnick G.H., Palta M. Temporal aspects of the electroretinogram in diabetic retinopathy. Arch. Ophthalmol. 1987, 105:660-664.
8. Carmo A., Cunha-Vaz J.G., Carvalho A.P., Lopes M.C. Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability. Nitric Oxide 2000, 4:590-596.
9. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., Lin J.K., Farzadfar F., Khang Y.H., Stevens G.A., Rao M., Ali M.K., Riley L.M., Robinson C.A., Ezzati M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40. Global burden of metabolic risk factors of chronic diseases collaborating group (blood glucose).
10. De Laurentiis A., Fernandez-Solari J., Mohn C., Burdet B., Zorrilla Zubilete M.A., Rettori V. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. J. Neuroimmunol. 2010, 221:32-41.
11. Hypoglycemia in the diabetes control and complications trial. Diabetes 1993, 46:271-286. Diabetes Control and Complications Trial Research Group.
12. Erickson P.A., Fisher S.K., Guerin C.J., Anderson D.H., Kaska D.D. Glial fibrillary acidic protein increases in Müller cells after retinal detachment. Exp. Eye Res. 1987, 44:37-48.
13. Gardner T.W., Antonetti D.A., Barber A.J., LaNoue K.F., Levison S.W. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 2002, 47:253-262.
14. Goralski K.B., Sinal C.J. Type 2 diabetes and cardiovascular disease: getting to the fat of the matter. Can. J. Physiol. Pharmacol. 2007, 85:113-132.
15. Hammes H.P., Federoff H.J., Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol. Med. 1995, 1:527-534.
16. Holopigian K., Seiple W., Lorenzo M., Carr R. A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 1992, 33:2773-2780.
17. Juen S., Kieselbach G.F. Electrophysiological changes in juvenile diabetics without retinopathy. Arch. Ophthalmol. 1990, 108:372-375.
18. Kaul K., Hodgkinson A., Tarr J.M., Kohner E.M., Chibber R. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?. Curr. Diabetes Rev. 2010, 6:294-303.
19. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
20. Li C., Cheng M., Yang H., Peachey N.S., Naash M.I. Age-related changes in the mouse outer retina. Optom. Vis. Sci. 2001, 78:425-430.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
22. Lutty G.A., McLeod D.S., Merges C., Diggs A., Plouét J. Localization of vascular endothelial growth factor in human retina and choroid. Arch. Ophthalmol. 1996, 114:971-977.
23. Matsui K., Ohta T., Oda T., Sasase T., Ueda N., Miyajima K., Masuyama T., Shinohara M., Matsushita M. Diabetes-associated complications in Spontaneously Diabetic Torii fatty rats. Exp. Anim. 2008, 57:111-121.
24. Matsumura T., Yamagishi S., Kodama Y., Shibata R., Ueda S., Narama I. Otsuka Long-Evan Tokushima Fatty (OLETF) rat is not a suitable animal model for the study of angiopathic diabetic retinopathy. Int. J. Tissue React. 2005, 27:59-62.
25. Mokini Z., Marcovecchio M.L., Chiarelli F. Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. Diabetes Res. Clin. Pract. 2010, 87:313-321.
26. Monnier L., Colette C., Dunseath G.J., Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007, 30:263-269.
27. Moreno M.C., Marcos H.J., Oscar Croxatto J., Sande P.H., Campanelli J., Jaliffa C.O., Benozzi J., Rosenstein R.E. A new experimental model of glaucoma in rats through intracameral injections of hyaluronic acid. Exp. Eye Res. 2005, 81:71-80.
28. Movassat J., Saulnier C., Portha B. Beta-cell mass depletion precedes the onset of hyperglycemia in the GK rat, a genetic model of non-insulin dependent diabetes mellitus. Diabetes Metab. 1995, 21:365-370.
29. Mühlhausler B.S. Nutritional models of type 2 diabetes mellitus. Methods Mol. Biol. 2009, 560:19-36.
30. Ng E.W., Adamis A.P. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. N. Y. Acad. Sci. 2006, 1082:151-171.
31. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
32. Osborne N.N., Block F., Sontag K.H. Reduction in ocular blood flow results in glial fibrillary acidic protein (GFAP) expression in rat Müller cells. Vis. Neurosci. 1991, 7:637-639.
33. Patel J., Iyer A., Brown L. Evaluation of the chronic complications of diabetes in a high fructose diet in rats. Indian J. Biochem. Biophys. 2009, 46:66-72.
34. Portha B., Blondel O., Serradas P., McEvoy R., Giroix M.H., Kergoat M., Bailbe D. The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabetes Metab. 1989, 15:61-75.
35. Shafrir E., Ziv E., Kalman R. Nutritionally induced diabetes in desert rodents as models of type 2 diabetes: Acomys cahirinus (spiny mice) and Psammomys obesus (desert gerbil). ILAR J. 2006, 47:212-224.
36. Srinivasan K., Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J. Med. Res. 2007, 125:451-472.
37. Srinivasan K., Viswanad B., Asrat L., Kaul C.L., Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 2005, 52:313-320.
38. Surwit R.S., Kuhn C.M., Cochrane C., McCubbin J.A., Feinglos M.N. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988, 37:1163-1167.
39. The Eye Diseases Research Prevalence Research Group-National Eye Institute The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol. 2004, 122:552-563.
40. Tzekov R., Arden G.B. The electroretinogram in diabetic retinopathy. Surv. Ophthalmol. 1999, 44:53-60.
41. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UK Prospective Diabetes Study (UKPDS) Group.
42. Wachtmeister L. Oscillatory potentials in the retina: what do they reveal. Prog. Retin. Eye Res. 1998, 17:485-521.
43. Weleber R.G. The effect of age on human cone and rod ganzfeld electroretinograms. Invest. Ophthalmol. Vis. Sci. 1981, 20:392-399.
44. Zheng L., Kern T.S. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front. Biosci. 2009, 14:3974-3987.